XII. DRUG COMBINATIONS THAT INCLUDE CAPECITABINE

The Meropol et al. (37) study administered the combination of irinotecan and cepecitabine in a clinical study of colorectal cancer. In a different clinical trial on colorectal cancer using a different drug combination (capecitabine plus oxiplatin), Petrioli et al. (38) also found that higher expression of **thymidine phosphorylase** is associated with a more favorable clinical response. The common use of drug combinations in oncology, and the frequent decision to change one of the drugs used in a two-drug combination therapy, raises the issue of synergy. In this context, synergy refers to an effect that is more than additive, as it applies to efficacy, and an effect that is more than additive, as it applies to toxicity. Aprile et al. (39) report that taxane drugs stimulate the expression of **thymidine phosphorylase**, and that this effect accounts for the increased anti-tumor activity of the combination of capecitabine and taxane. Kikuno et al. (40) report the induction of this enzyme, with use of the taxane, paclitaxel.

XIII. METHODOLOGY TIP – DO CHANGES IN mRNA EXPRESSION RESULT IN CORRESPONDING CHANGES IN EXPRESSION OF POLYPEPTIDE?

Meropol et al. (41) measured expression of thymidine phosphorylase with immunological assays sensitive to the polypeptide, and with PCR-based assays sensitive to the expressed mRNA. As a general proposition, it is hoped that changes in mRNA expression correlate with changes in the polypeptide. But it must not be assumed that an increase in mRNA results in a corresponding increase in protein. Pennica et al. (42) Haynes et al. (43) Hu et al. (44) Oh et al. (45) Schantz and Pegg (46) and Anderson

[37] Meropol NJ, Gold PJ, Diasio RB, et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. *J Clin Oncol*. 2006;24:4069–4077.

[38] Petrioli R, Bargagli G, Lazzi S, et al. Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. *Anticancer Drugs*. 2010;21:313–319.

[39] Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. *Anticancer Drugs*. 2009;20:217–229.

[40] Kikuno N, Moriyama-Gonda N, Yoshino T, et al. Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells. *Cancer Res*. 2004;64:7526–7532.

[41] Meropol NJ, Gold PJ, Diasio RB, et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. *J Clin Oncol*. 2006;24:4069–4077.

[42] Pennica D, Swanson TA, Welsh JW, et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. *Proc Natl Acad Sci USA*. 1998;95:14717–14722.

[43] Haynes PA, Gygi SP, Figeys D, Aebersold R. Proteome analysis: biological assay or data archive? *Electrophoresis*. 1998;19:1862–1871.

[44] Hu Y, Hines LM, Weng H, Zuo D, Rivera M, Richardson A, et al. Analysis of genomic and proteomic data using advanced literature mining. *J Proteome Res*. 2003;2:405–412.

[45] Oh JM, Brichory F, Puravs E, et al. A database of protein expression in lung cancer. *Proteomics*. 2001;1:1303–1319.

[46] Shantz LM, Pegg AE. Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway. *Int J Biochem Cell Biol*. 1999;31:107–122.